Fragment Of RegeneRx's T(beta)4 Inhibits Activation Of Liver Cells Responsible Fibrosis & Scar Formation

[Guest guest]

Fragment Of RegeneRx's T(beta)4 Inhibits Activation Of Liver Cells Responsible Fibrosis & Scar Formation

RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") has announced that researchers have found that a fragment of T(beta)4 has the ability to inhibit a type of liver cell responsible for fibrosis and scar formation by blocking the binding of AKT to actin. AKT is an important enzyme that regulates cell death; actin is responsible for cell contraction and movement. The molecule responsible for this activity is a seven amino acid fragment of T(beta)4 known to be the acting binding domain of T(beta)4. According to the researchers these data make possible the development of a novel therapeutic that can specifically identify and target cells responsible for the excessive scarring seen in liver diseases such as cirrhosis, as well as potential pathologies of the lungs, kidneys and other organs.

The research team was led by Dr. Marcos Rojkind of the Department of Biochemistry and Molecular Biology at The Washington University School of Medicine. The research results will be reported at the annual meeting of the American Society for Investigative Pathology held with the Federation of American Societies of Experimental Biology (FASEB) on Tuesday, April 12, 2011. Source: RegeneRx Biopharmaceuticals, Inc.

http://www.medicalnewstoday.com/articles/222101.php